Insider Selling: Equillium (NASDAQ:EQ) COO Sells $240,833.60 in Stock

Equillium, Inc. (NASDAQ:EQ) COO Christine Zedelmayer sold 86,012 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $2.80, for a total transaction of $240,833.60. Following the transaction, the chief operating officer directly owned 62,586 shares of the company’s stock, valued at $175,240.80. The trade was a 57.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Zedelmayer also recently made the following trade(s):

• On Wednesday, May 27th, Christine Zedelmayer sold 9,821 shares of Equillium stock. The stock was sold at an average price of $2.70, for a total transaction of $26,516.70.
• On Friday, March 13th, Christine Zedelmayer sold 120,312 shares of Equillium stock. The stock was sold at an average price of $2.50, for a total transaction of $300,780.00.
• On Monday, March 9th, Christine Zedelmayer sold 181,219 shares of Equillium stock. The stock was sold at an average price of $2.00, for a total transaction of $362,438.00.

Equillium Stock Performance

NASDAQ:EQ opened at $2.90 on Monday. The company has a 50-day moving average of $2.11 and a 200-day moving average of $1.64. The company has a market capitalization of $183.37 million, a price-to-earnings ratio of -9.06 and a beta of 1.77. Equillium, Inc. has a 52 week low of $0.27 and a 52 week high of $3.10.

Equillium (NASDAQ:EQ) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). Sell-side analysts forecast that Equillium, Inc. will post -0.24 EPS for the current year.

Key Equillium News

Here are the key news stories impacting Equillium this week:

• Positive Sentiment: Leerink Partners upgraded Equillium from market perform to outperform and lifted its price target to $6.00, suggesting meaningful upside from current levels. Leerink Upgrades Equillium (EQ) to Outperform
• Positive Sentiment: Roth Mkm reiterated a buy rating and set a $12.00 target, reinforcing a bullish view on Equillium’s pipeline and valuation. Equillium Receives Buy Rating from Roth Mkm
• Positive Sentiment: Equillium announced it will participate in the 2026 Jefferies Global Healthcare Conference, which could provide a catalyst if management shares favorable clinical or strategic updates. Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
• Positive Sentiment: Shareholders approved a reverse split and capital changes at the annual meeting, a step that can help maintain Nasdaq compliance and potentially improve the company’s capital structure. Equillium Shareholders Approve Reverse Split and Capital Changes
• Neutral Sentiment: Short interest was reported at 0 shares, indicating no meaningful bearish positioning in the latest update, though the figure appears unusual and may not be a reliable market signal. Short interest update
• Negative Sentiment: COO Christine Zedelmayer sold a combined 95,833 shares over two transactions, and insider Penny Tom sold 65,000 shares; although both were made under pre-arranged 10b5-1 plans, insider selling can still pressure sentiment. SEC Form 4 insider sales filing

Institutional Trading of Equillium

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Janus Henderson Group PLC acquired a new position in Equillium during the 4th quarter worth $9,057,000. ADAR1 Capital Management LLC acquired a new stake in shares of Equillium in the 3rd quarter valued at $7,951,000. Woodline Partners LP acquired a new stake in shares of Equillium in the 3rd quarter valued at $5,018,000. Aberdeen Group plc raised its position in shares of Equillium by 523.6% during the fourth quarter. Aberdeen Group plc now owns 2,366,688 shares of the company’s stock worth $3,668,000 after acquiring an additional 1,987,162 shares during the last quarter. Finally, Eversept Partners LP bought a new stake in shares of Equillium during the first quarter worth $2,998,000. Institutional investors and hedge funds own 27.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on EQ shares. Stifel Nicolaus set a $5.00 target price on shares of Equillium in a research report on Thursday. Wall Street Zen cut shares of Equillium from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Cantor Fitzgerald assumed coverage on shares of Equillium in a research report on Tuesday, April 7th. They set an “overweight” rating and a $10.00 target price for the company. Leerink Partners raised Equillium from a “market perform” rating to an “outperform” rating and raised their price target for the company from $1.00 to $6.00 in a report on Thursday. Finally, B. Riley Financial began coverage on Equillium in a research report on Thursday, April 16th. They issued a “buy” rating and a $6.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Equillium has an average rating of “Moderate Buy” and an average price target of $7.57.

Equillium Company Profile

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.